Computer Designed Antiviral Treatment
Pan-Viral Treatment Design – Corona, Influenza, Ebola
- Exclusive license and sponsored research agreement
- Collaborating with UMB to optimize licensed candidates
- Additional lead compounds recently identified
- Dr. Matthew B. Frieman, Ph.D. is lead inventor
- Drugs effective against Influenza virus, SARS-CoV, MERS-CoV, SARS-CoV-2 and others
- Computer modeling ID’d binding pockets on SKI
- Drug structures designed by computer modeling
- Synthesis and screening ID’d lead candidates
- Drug structures currently being optimized
- Dr. Frieman is working to identify novel and repurposed drugs, antibodies and vaccines for Influenza virus, SARS-CoV, MERS-CoV and SARS-CoV-2 inhibition
- Data on first lead compounds was recently published at:
Weston et al. (2020) The SKI complex is a broad-spectrum, host-directed antiviral drug target for coronaviruses, influenza, and filoviruses PNAS 117 (48) 30687-30698, https://doi.org/10.1073/pnas.2012939117
- SKI complex identified as a potential broad-spectrum antiviral target
- Initial data suggested functional link between viral proteins and SKI
- Computer modeling identified potential drug binding pockets on SKI
- Computer modeling to design compounds to bind SKI pockets
- Screening identified specific compounds that inhibit various viruses
- Inhibited viruses include influenza, Ebola and Corona
Source: https://www.cell.com/fulltext/S0092–8674(13)00888–X
Cell 2013 154814-826 DOI: (10.1016/j.cell.2013.07.017)
Halbach et al. (2013) “The Yeast Ski Complex: Crystal Structure and RNA Channeling to the Exosome Complex” Cell 154:814-826